Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
Combination dabrafenib (D) and trametinib (T) is an FDA approved adjuvant therapy for patients with resected stage III BRAF-mutant melanoma. We describe treatment-related toxicities with adjuvant D+T in a real-world population through a retrospective case series. The primary endpoint was development...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Frontiers Media S.A.
2022-09-01
|
| Σειρά: | Frontiers in Oncology |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.frontiersin.org/articles/10.3389/fonc.2022.855794/full |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|